Baylor‘s Human Genome Sequencing Center will help Mayo Clinic sequence the DNA of Mayo biobank members for 69 different genes that can influence how patients’ metabolize or react to different drugs.
The goal is to determine which “pharmacogenomic” findings are relevant to the individual patient and to insert that information into their medical records – providing an “early warning system” to prevent adverse drug reactions or ineffective treatments.
› Read BCM's Momentum blog story
› Read news release from Mayo Clinic
The sequence and analysis of the gibbon genome was published today in the journal Nature and led by scientists at Oregon Health & Science University, the Baylor College of Medicine Human Genome Sequencing Center and the Washington University School of Medicine’s Genome Institute.
Image courtesy of Nature Publishing Group
|Image source: Sang Eun Lee, Samsung Medical Center|
Researchers in The Cancer Genome Atlas (TCGA) Network have made a number of new findings about the biology and development of a rare form of kidney cancer.
Dr. Caleb Davis and Dr. Min Wang of the BCM-HGSC are co-first authors on the paper, The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma, which appeared August 21, 2014 in Cancer Cell.
The development and clinical implementation of the Whole Exome Sequencing test derives from a joint effort by Baylor's Human Genome Sequencing Center and Baylor Miraca Genetics Laboratories to establish a clinical laboratory dedicated to state-of-the-art next generation sequencing.